Participant Disposition and Demographics
narcolepsy
NARCOLEPSY, NARCOLEPSY TYPE 1, DISEASE CHARACTERISTIC
As described previously, 222 participants were enrolled and randomly assigned to either ON-SXB or placebo (Baseline demographics and disease characteristics (safety population)BMI, body mass index; NT1, narcolepsy type 1; NT2, narcolepsy type 2; ON-SXB, once-nightly sodium oxybate (FT218).Baseline measurements (mITT population)ESS, Epworth Sleepiness Scale; mITT, modified intent-to-treat; NT1, narcolepsy type 1; NT2, narcolepsy type 2; ON-SXB, once-nightly sodium oxybate (FT218); VAS, visual analog scale.